Quinolinate salvage and insights for targeting NAD biosynthesis in group A streptococci

Journal of Bacteriology

Volumn 195, Issue 4, 2013, Pages 726-732

  Sorci, Leonardo ^a,b   Blaby, Ian K ^c,e   Rodionova, Irina A ^a   De Ingeniis, Jessica ^a   Tkachenko, Sergey ^d   de Crécy Lagard, Valérie ^c   Ostermana, Andrei L ^a  

^a BURNHAM INSTITUTE   (United States)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c UNIVERSITY OF FLORIDA   (United States)

^d CHEMDIV INC   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINAMIDASE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINIC ACID; PHOSPHORIBOSYLTRANSFERASE; QUINOLINIC ACID;

ARTICLE; AUXOTROPHY; BACTERIAL GENE; BACTERIAL GROWTH; BIOSYNTHESIS; ENZYME ACTIVITY; ENZYME SYNTHESIS; IC 50; METABOLISM; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS EQUI; STREPTOCOCCUS GORDONII; STREPTOCOCCUS GROUP A; STREPTOCOCCUS MITIS; STREPTOCOCCUS MUTANS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; STREPTOCOCCUS SANGUINIS; STREPTOCOCCUS SUIS; STREPTOCOCCUS THERMOPHILUS; STREPTOCOCCUS UBERIS;

AMIDE SYNTHASES; BACTERIAL PROTEINS; CLONING, MOLECULAR; GENE EXPRESSION REGULATION, BACTERIAL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; MUTATION; NAD; NIACIN; NICOTINAMIDE-NUCLEOTIDE ADENYLYLTRANSFERASE; QUINOLINIC ACID; STREPTOCOCCUS PYOGENES;

EID: 84873642708     PISSN: 00219193     EISSN: 10985530     Source Type: Journal    
DOI: 10.1128/JB.02002-12     Document Type: Article

References (47)

1. Cunningham MW. 2000. Pathogenesis of group A streptococcal infections. Clin. Microbiol. Rev. 13:470-511.
2. Gillespie SH, Balakrishnan I. 2000. Pathogenesis of pneumococcal infection. J. Med. Microbiol. 49:1057-1067.
3. Morens DM, Folkers GK, Fauci AS. 2004. The challenge of emerging and re-emerging infectious diseases. Nature 430:242-249.
4. Sorci L, Kurnasov O, Rodionov DA, Osterman AL. 2010. Genomics and enzymology of NAD biosynthesis, p 213-257. In Lew M, Hung-Wen L (ed), Comprehensive natural products II. Elsevier, Oxford, United Kingdom.
5. Gazzaniga F, Stebbins R, Chang SZ, McPeek MA, Brenner C. 2009. Microbial NAD metabolism: lessons from comparative genomics. Microbiol. Mol. Biol. Rev. 73:529-541.
6. Boshoff HI, Xu X, Tahlan K, Dowd CS, Pethe K, Camacho LR, Park TH, Yun CS, Schnappinger D, Ehrt S, Williams KJ, Barry CE, III. 2008. Biosynthesis and recycling of nicotinamide cofactors in Mycobacterium tuberculosis. An essential role for NAD in nonreplicating bacilli. J. Biol. Chem. 283:19329-19341.
7. Gerdes SY, Scholle MD, D'Souza M, Bernal A, Baev MV, Farrell M, Kurnasov OV, Daugherty MD, Mseeh F, Polanuyer BM, Campbell JW, Anantha S, Shatalin KY, Chowdhury SA, Fonstein MY, Osterman AL. 2002. From genetic footprinting to antimicrobial drug targets: examples in cofactor biosynthetic pathways. J. Bacteriol. 184:4555-4572.
8. Osterman AL, Begley TP. 2007. A subsystems-based approach to the identification of drug targets in bacterial pathogens. Prog. Drug Res. 64: 131, 133-170.
9. Sorci L, Blaby I, De Ingeniis J, Gerdes S, Raffaelli N, de Crecy Lagard V, Osterman A. 2010. Genomics-driven reconstruction of acinetobacter NADmetabolism: insights for antibacterial target selection. J. Biol. Chem. 285:39490-39499.
10. Sorci L, Martynowski D, Rodionov DA, Eyobo Y, Zogaj X, Klose KE, Nikolaev EV, Magni G, Zhang H, Osterman AL. 2009. Nicotinamide mononucleotide synthetase is the key enzyme for an alternative route of NAD biosynthesis in Francisella tularensis. Proc. Natl. Acad. Sci. U. S. A. 106:3083-3088.
11. Haferkamp I, Schmitz-Esser S, Linka N, Urbany C, Collingro A, Wagner M, Horn M, Neuhaus HE. 2004. A candidate NAD+ transporter in an intracellular bacterial symbiont related to Chlamydiae. Nature 432: 622-625.
12. De Ingeniis J, Kazanov MD, Shatalin K, Gelfand MS, Osterman AL, Sorci L. 2012. Glutamine versus ammonia utilization in the NAD synthetase family. PLoS One 7:e39115. doi:10.1371/journal.pone.0039115.
13. Sorci L, Pan Y, Eyobo Y, Rodionova I, Huang N, Kurnasov O, Zhong S, MacKerell AD, Jr, Zhang H, Osterman AL. 2009. Targeting NAD biosynthesis in bacterial pathogens: structure-based development of in- hibitors of nicotinate mononucleotide adenylyltransferase NadD. Chem. Biol. 16:849-861.
14. Huang N, Kolhatkar R, Eyobo Y, Sorci L, Rodionova I, Osterman AL, Mackerell AD, Zhang H. 2010. Complexes of bacterial nicotinate mononucleotide adenylyltransferase with inhibitors: implication for structurebased drug design and improvement. J. Med. Chem. 53:5229-5239.
15. Moro WB, Yang Z, Kane TA, Zhou Q, Harville S, Brouillette CG, Brouillette WJ. 2009. SAR studies for a new class of antibacterial NAD biosynthesis inhibitors. J. Comb. Chem. 11:617-625.
16. Moro WB, Yang Z, Kane TA, Brouillette CG, Brouillette WJ. 2009. Virtual screening to identify lead inhibitors for bacterial NAD synthetase (NADs). Bioorg. Med. Chem. Lett. 19:2001-2005.
17. Velu SE, Mou L, Luan CH, Yang ZW, DeLucas LJ, Brouillette CG, Brouillette WJ. 2007. Antibacterial nicotinamide adenine dinucleotide synthetase inhibitors: amide- and ether-linked tethered dimers with alpha- amino acid end groups. J. Med. Chem. 50:2612-2621.
18. Plata G, Hsiao TL, Olszewski KL, Llinas M, Vitkup D. 2010. Reconstruction and flux-balance analysis of the Plasmodium falciparum metabolic network. Mol. Syst. Biol. 6:408.
19. Kurnasov OV, Polanuyer BM, Ananta S, Sloutsky R, Tam A, Gerdes SY, Osterman AL. 2002. Ribosylnicotinamide kinase domain of NadR protein: identification and implications in NAD biosynthesis. J. Bacteriol. 184:6906-6917.
20. Reinhard JF, Jr, Erickson JB, Flanagan EM. 1994. Quinolinic acid in neurological disease: opportunities for novel drug discovery. Adv. Pharmacol. 30:85-127.
21. Schwarcz R. 2004. The kynurenine pathway of tryptophan degradation as a drug target. Curr. Opin. Pharmacol. 4:12-17.
22. Overbeek R, Begley T, Butler RM, Choudhuri JV, Chuang Cohoon H-YM, de Crecy-Lagard V, Diaz N, Disz T, Edwards R, Fonstein M, Frank ED, Gerdes S, Glass EM, Goesmann A, Hanson A, Iwata-Reuyl D, Jensen R, Jamshidi N, Krause L, Kubal M, Larsen N, Linke B, McHardy AC, Meyer F, Neuweger H, Olsen G, Olson R, Osterman A, Portnoy V, Pusch GD, Rodionov DA, Ruckert C, Steiner J, Stevens R, Thiele I, Vassieva O, Ye Y, Zagnitko O, Vonstein V. 2005. The subsystems approach to genome annotation and its use in the project to annotate 1000 genomes. Nucleic Acids Res. 33:5691-5702.
23. Novichkov PS, Laikova ON, Novichkova ES, Gelfand MS, Arkin AP, Dubchak I, Rodionov DA. 2010. RegPrecise: a database of curated genomic inferences of transcriptional regulatory interactions in prokaryotes. Nucleic Acids Res. 38:D111-D118.
24. Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W, Lopez R, McWilliam H, Remmert M, Soding J, Thompson JD, Higgins DG. 2011. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol. Syst. Biol. 7:539.
25. van de Rijn I, Kessler RE. 1980. Growth characteristics of group A streptococci in a new chemically defined medium. Infect. Immun. 27: 444-448.
26. Osterman AL, Lueder DV, Quick M, Myers D, Canagarajah BJ, Phillips MA. 1995. Domain organization and a protease-sensitive loop in eukaryotic ornithine decarboxylase. Biochemistry 34:13431-13436.
27. Daugherty M, Vonstein V, Overbeek R, Osterman A. 2001. Archaeal shikimate kinase, a new member of the GHMP-kinase family. J. Bacteriol. 183:292-300.
28. Cao H, Pietrak BL, Grubmeyer C. 2002. Quinolinate phosphoribosyltransferase: kinetic mechanism for a type II PRTase. Biochemistry 41: 3520-3528.
29. Lyon RP, Atkins WM. 2002. Kinetic characterization of native and cysteine 112-modified glutathione S-transferase A1-1: reassessment of nonsubstrate ligand binding. Biochemistry 41:10920-10927.
30. Osterman A, Overbeek R. 2003. Missing genes in metabolic pathways: a comparative genomics approach. Curr. Opin. Chem. Biol. 7:238-251.
31. Rodionov DA, Li X, Rodionova IA, Yang C, Sorci L, Dervyn E, Martynowski D, Zhang H, Gelfand MS, Osterman AL. 2008. Transcriptional regulation of NAD metabolism in bacteria: genomic reconstruction of NiaR (YrxA) regulon. Nucleic Acids Res. 36:2032-2046.
32. Rodionov DA, Hebbeln P, Eudes A, ter Beek J, Rodionova IA, Erkens GB, Slotboom DJ, Gelfand MS, Osterman AL, Hanson AD, Eitinger T. 2009. A novel class of modular transporters for vitamins in prokaryotes. J. Bacteriol. 191:42-51.
33. Kurnasov O, Goral V, Colabroy K, Gerdes S, Anantha S, Osterman A, Begley TP. 2003. NAD biosynthesis: identification of the tryptophan to quinolinate pathway in bacteria. Chem. Biol. 10:1195-1204.
34. Prunier AL, Schuch R, Fernandez RE, Mumy KL, Kohler H, McCormick BA, Maurelli AT. 2007. nadA and nadB of Shigella flexneri 5a are antivirulence loci responsible for the synthesis of quinolinate, a small molecule inhibitor of Shigella pathogenicity. Microbiology 153:2363-2372.
35. Prunier AL, Schuch R, Fernandez RE, Maurelli AT. 2007. Genetic structure of the nadA and nadB antivirulence loci in Shigella spp. J. Bacteriol. 189:6482-6486.
36. Fujiwara S, Kobayashi S, Nakayama H. 1978. Development of a minimal medium for Streptococcus mutans. Arch. Oral Biol. 23:601-602.
37. Bhatia R, Calvo KC. 1996. The sequencing expression, purification, and steady-state kinetic analysis of quinolinate phosphoribosyl transferase from Escherichia coli. Arch. Biochem. Biophys. 325:270-278.
38. Liu H, Woznica K, Catton G, Crawford A, Botting N, Naismith JH. 2007. Structural and kinetic characterization of quinolinate phosphoribosyltransferase (hQPRTase) fromHomosapiens. J. Mol. Biol. 373:755-763.
39. Rongvaux A, Shea RJ, Mulks MH, Gigot D, Urbain J, Leo O, Andris F. 2002. Pre-B-cell colony-enhancing factor, whose expression is upregulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur. J. Immunol. 32:3225-3234.
40. Lu S, Smith CD, Yang Z, Pruett PS, Nagy L, McCombs D, Delucas LJ, Brouillette WJ, Brouillette CG. 2008. Structure of nicotinic acid mononucleotide adenylyltransferase from Bacillus anthracis. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 64:893-898.
41. Olland AM, Underwood KW, Czerwinski RM, Lo MC, Aulabaugh A, Bard J, Stahl ML, Somers WS, Sullivan FX, Chopra R. 2002. Identification, characterization, and crystal structure of Bacillus subtilis nicotinic acid mononucleotide adenylyltransferase. J. Biol. Chem. 277:3698-3707.
42. Lefebure T, Richards VP, Lang P, Pavinski-Bitar P, Stanhope MJ. 2012. Gene repertoire evolution of Streptococcus pyogenes inferred from phylogenomic analysis with Streptococcus canis and Streptococcus dysgalactiae. PLoS One 7:e37607. doi:10.1371/journal.pone.0037607.
43. Carlin JM, Ozaki Y, Byrne GI, Brown RR, Borden EC. 1989. Interferons and indoleamine 2,3-dioxygenase: role in antimicrobial and antitumor effects. Experientia 45:535-541.
44. Scott JR, Guenthner PC, Malone LM, Fischetti VA. 1986. Conversion of an M- group A streptococcus to M+ by transfer of a plasmid containing an M6 gene. J. Exp. Med. 164:1641-1651.
45. Biswas I, Scott JR. 2003. Identification of rocA, a positive regulator of covR expression in the group A streptococcus. J. Bacteriol. 185:3081-3090.
46. Sorci L, Cimadamore F, Scotti S, Petrelli R, Cappellacci L, Franchetti P, Orsomando G, Magni G. 2007. Initial-rate kinetics of human NMNadenylyltransferases: substrate and metal ion specificity, inhibition byproducts and multisubstrate analogues, and isozyme contributions to NAD+ biosynthesis. Biochemistry 46:4912-4922.
47. Berger F, Lau C, Dahlmann M, Ziegler M. 2005. Subcellular compartmentation and differential catalytic properties of the three human nicotinamide mononucleotide adenylyltransferase isoforms. J. Biol. Chem. 280: 36334-36341. Sorci et al. 732